13th ANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE
An Educational Course on Translating Research into Drugs
Presented by the Alzheimer’s Drug Discovery Foundation
March 17-19, 2019 • Long Beach, CA

Program

2019 PRELIMINARY PROGRAM

All sessions will be held at the Renaissance Long Beach Hotel located at 111 East Ocean Boulevard, Long Beach, CA 90802.

SUNDAY, March 17, 2019
2:00pm - 5:10Registration
2:00 - 3:00EARLY CAREER INVESTIGATORS CAREER PANEL: Job Opportunities in Drug Discovery (Q&A after panel)
Moderator: Alessio Travaglia, PhD—Alzheimer’s Drug Discovery Foundation

Foundation Representatives: Walter Kostich (National MS Society) & Kuldip Dave (MJFF for PD Research)
Government Representatives: Lorenzo Refolo (NIA)
Biotech Representatives: Marcie Glicksman (Orig3n Inc.)
Academic Drug Discovery: Kurt Brunden (University of Pennsylvania)
3:00 - 3:50How to Land the Job: Cover Letter, Resume and Interview Skills Workshop
David Blancha, PhD—UCLA
4:00 - 4:20Welcome & Opening Remarks: Challenges and Opportunities in Academic Drug Discovery
Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
4:20 - 5:00KEYNOTE: Increasing Efficiency, Safety, and Speed in Clinical Trials for Neurodegenerative Diseases
Diane Stephenson, PhD—Critical Path Institute
5:00 - 5:10Q&A
5:10 - 7:00Welcoming Reception
MONDAY, March 18, 2019
7:30am - 5:00 pmRegistration
7:30am - 8:30Breakfast
8:30 - 8:40Opening Remarks and ADDF Funding Opportunities
Meriel Owens—Alzheimer's Drug Discovery Foundation
8:40 - 8:50NIA Opportunities for Translational Research Funding
Zane Martin, PhD—National Institutes of Health, National Institute on Aging
8:50 - 9:00NINDS Opportunities for Translational Research Funding
Amir Tamiz, PhD—National Institutes of Health, National Institute of Neurological Disorders and Stroke
Session I. EMBARKING ON A DRUG DISCOVERY CAMPAIGN
Chair: Marcie Glicksman, PhD—Orig3n, Inc.
9:00 - 9:05Session Overview:
Marcie Glicksman, PhD—Orig3n, Inc.
9:05 - 9:25What Makes a Good Drug Target? A Perspective in Neurodegenerative Disease Therapeutic Discovery
Sam Hasson, PhD—Amgen
9:25 - 9:35Q&A
9:35 - 9:55High Throughput Screening and Assay Development
Scott Sneddon, JD, PhD—Sharp Edge Labs
9:55 - 10:05Q&A
10:05 - 10:25Medicinal Chemistry Basics
TBA
10:25 - 10:35Q&A
10:35 - 11:00EXHIBITOR SESSION AND BREAK
Session II. DRUG DISCOVERY: FROM LEAD TO CLINICAL CANDIDATE
Chair: D. Martin Watterson, PhD—Northwestern University
11:00 - 11:05Session Overview:
D. Martin Watterson, PhD—Northwestern University
11:05 - 11:25Secondary Pharmacology in Lead Compound Development and Risk Reduction in CNS Disease Drug Discovery
D. Martin Watterson, PhD—Northwestern University
11:25 - 11:35Q&A
11:35 - 11:55PK/PD in Preclinical Development
Isabel Gonzalez, PhD—Drug Discovery and Development Consultants Ltd
11:55am - 12:05pmQ&A
12:05 - 12:25Improving the Translatability of Animal Models of Neurodegeneration
Birgit Hutter-Paier, PhD – QPS Austria
12:25 - 12:35Q&A
12:35–1:00YOUNG INVESTIGATOR SCHOLARSHIP POSTER SESSION
Poster Abstracts #1-12
1:00 - 2:00LUNCH
Session III. ACCELERATING THERAPIES INTO CLINICAL TRIALS
Chair: Edward Spack, PhD—MedaRed, Inc.
2:00 - 2:05Session Overview:
Edward Spack, PhD—MedaRed, Inc.
2:05 - 2:25Requirements for an IND
Edward Spack, PhD—MedaRed, Inc.
2:25 - 2:35Q&A
2:35 - 2:55The Role of Fluid Biomarkers in Clinical Trials
Robert Fox, MD—Cleveland Clinic
2:55 - 3:05Q&A
3:05 - 3:25The Role of PET Biomarkers in Clinical Trials
Adam Fleisher, MD—Avid Radiopharmaceuticals
3:25 - 3:35Q&A
3:35 - 3:55The Role of Digital Biomarkers in Clinical Trials
TBA
3:55 - 4:05Q&A
4:05 - 4:25EXHIBITOR SESSION and BREAK
4:25 - 4:45Designing Early Stage Clinical Trials for Neurodegenerative Diseases
Suzanne Hendrix, PhD—Pentara Corporation
4:45 - 4:55Q&A
4:55 - 5:15Choosing the right people: consideration in selection and inclusion of clinical trial population
Richard Margolin, MD—CNS Research Solutions
5:15 - 5:25Q&A
5:25 - 5:30Young Investigator Scholarship Awards Presented
Nicole Bjorklund—Alzheimer’s Drug Discovery Foundation
5:40 - 6:30Mentoring Session (pre-registration required)
5:30 - 7:20Networking Reception
TUESDAY, March 19, 2019
7:30am - 3:20 pmRegistration
7:30am - 8:00Mentoring Session (pre-registration required)
7:30 - 8:20Continental Breakfast
8:20 - 8:25Welcome & Opening Remarks
Elizabeth Mills—Alzheimer’s Drug Discovery Foundation
8:25 - 9:05KEYNOTE:
Gene Therapy Approaches for Neurodegenerative Diseases

TBA
9:05 - 9:15Q&A
Session IV. STRATEGIES FOR CHALLENGING CNS TARGETS: CASE STUDY EXAMPLES
Chair: Kurt Brunden, PhD—University of Pennsylvania
9:15 - 9:20Session Overview:
Kurt Brunden, PhD—University of Pennsylvania
9:20 - 9:40Case Study on Stem Cells
Marcie Glicksman, PhD—Orig3n Inc.
9:40 - 9:50Q&A
9:50 - 10:10Designing Combination Therapies Trials for ALS and Alzheimer’s Disease
Kent Leslie, M.Sc—Amylyx
10:10 - 10:20Q&A
10:20 - 10:40EXHIBITOR SESSION and BREAK
10:40 - 11:00Case Study on Inflazome Program
David Miller, PhD—Inflazome
11:00 - 11:10Q&A
11:10 - 11:30The Intersection of the Brain, Immune, and Vascular Systems
Katerina Akassoglou, PhD—University of California San Francisco
11:30 - 11:40Q&A
11:40 - 12:00pmLessons Learned in Drug Development from an Academic and Small Biotech Perspective
Frank Longo, MD, PhD—Stanford University & PharmatrophiX
12:00 - 12:10Q&A
12:10 - 12:40YOUNG INVESTIGATOR SCHOLARSHIP POSTER SESSION
Poster Abstracts #13-24
12:40 - 1:40LUNCH
Session V. BUILDING THE INFRASTRUCTURE TO COMMERCIALIZE SCIENCE INTO PRODUCTS
Chair: Frank Longo, MD, PhD—Stanford University & PharmatrophiX
1:40 - 1:45Session Overview:
Frank Longo, MD, PhD—Stanford University & PharmatrophiX
1:45 - 2:05Working with Your Tech Transfer Office to Commercialize Technologies
TBA
2:05-2:15Q&A
2:15 - 2:35How to Pitch an Idea to Investors with Total Confidence
Shobha Parthasarathi, PhD—Harrington Discovery Institute
2:35 - 2:45Q&A
2:45 - 3:05Working with Pharma Venture
Rana Al-Hallaq, PhD—Pfizer Inc.
3:05 - 3:15Q&A
3:15 - 3:20Closing Remarks
Howard Fillit, MD—Alzheimer's Drug Discovery Foundation